Bright Minds Biosciences Shares to Commence Trading on the OTCQB Venture Market on May 17, 2021
May 17, 2021 06:50 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, May 17, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on...
Bright Minds Biosciences to Present at the Benzinga Global Small Cap Conference
May 11, 2021 08:00 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG), a biotechnology company focused on developing novel...
Bright Minds Biosciences Appoints Industry Experts for Key Roles and Expands Scientific Advisory Team
April 27, 2021 08:00 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, April 27, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel transformative...
Bright Minds Biosciences Announces Closing of $25.9 Million Unit Offering
March 17, 2021 12:30 ET
|
Bright Minds Biosciences
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British...
Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows an Over 50% Decrease in Opioid Self-Administration in a Predictive Rodent Model
March 15, 2021 08:00 ET
|
Bright Minds Biosciences
-- BMB compound significantly reduced fentanyl intake in an animal model of opioid abuse -- -- Potential to reduce continued opioid use in humans, a key treatment goal for opioid use disorder -- --...
Bright Minds Biosciences to Present at the Stifel GMP Healthcare Conference - Healthcare Psychedelics: Addressing the Global Mental Health Crisis
March 10, 2021 08:00 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, March 10, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG), a biotechnology company focused on developing novel...
Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonists Show Significant Reduction in Binge Eating
March 03, 2021 08:00 ET
|
Bright Minds Biosciences
-- Model is predictive for human efficacy for binge eating -- -- BMB compound reduced binge eating in rats with a clear dose range for efficacy -- -- A virtual presentation discussing the findings...
Bright Minds Biosciences Strengthens Scientific Advisory Team to Prepare for Future Growth
February 10, 2021 08:00 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds” or the “Company”), a biosciences company focused on creating the next generation of...
Bright Minds Biosciences Announces Listing on Canadian Stock Exchange
February 05, 2021 11:30 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds” or the “Company”), a biosciences company focused on creating the next generation of...